Prostate cancer is an extremely common disease that affects one out of every seven men in their lifetime. Our laboratory works to better understand the molecular underpinnings of prostate cancer to develop more effectively treat this common disease.


Recent Publications

Şeref, C., Acar, Ö., Kılıç, M., Vural, M., Sağlıcan, Y., Saraç, H., Coşkun, B., İnce, Ü., Esen, T., & Lack, N. A. (2021). Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations. The Prostate. doi: 10.1002/pros.24255

Leblanc, E., Ban, F., Cavga, A. D., Lawn, S., Huang, C. F., Mohan, S., Chang, M., Flory, M. R., Ghaidi, F., Lingadahalli, S., Chen, G., Yu, I., Morin, H., Lallous, N., Gleave, M. E., Mohammed, H., Young, R. N., Rennie, P. S., Lack, N. A., & Cherkasov, A. (2021). Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. Journal of Medicinal Chemistry. doi: 10.1021/acs.jmedchem.1c00681